Oloker’s breakthrough technology consists of  a proprietary method for cardiac cell manufacturing and  a proprietary human cardiac pro-angiogenic, CPC product (Cardiac Pro-angiogenic Cells Plus). In particular, the manufacturing process includes an innovative fully GMP-compliant high-efficient and cost-effective scalable method to isolate CPC both in autologous and allogenic settings. CPCPlus is therefore classified, according to EMA guidelines and EU legislation, as Advanced Therapy Medicinal Product (ATMP), specifically conceived to exert a potent angiogenic effect to the ischemic myocardium and with high immunomodulatory capacity. The invention tackles the unmet clinical need of a specific subset of patients with advanced coronary artery disease, who are considered no longer suitable for state-of-the-art cures by means of medical therapy and conventional revascularization techniques (bypass surgery/coronary stenting). This population of no-option patients experience a dramatically poor quality of life due to so called “refractory angina”. The CPCPlus platform will be subsequently exploited to expand the possible clinical applications to other cardiovascular ischemic and non-ischemic disease.